Skip to main content

AL Amyloidosis clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for
  • Screening to Improve Survival in AL Amyloidosis

    open to eligible people ages 60 years and up

    The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.

    Orange, California and other locations

  • S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

    Sorry, in progress, not accepting new patients

    This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

    Orange, California and other locations

Our lead scientists for AL Amyloidosis research studies include .

Last updated: